Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 446-456

  Gomez, Delphine ^a,b   Coyet, Aurélie ^c   Ollivier, Véronique ^a,b   Jeunemaitre, Xavier ^c,d   Jondeau, Guillaume ^a,b   Michel, Jean Baptiste ^a,b   Vranckx, Roger ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

Author keywords

Histone acetylation; Marfan syndrome; Smad; Smooth muscle cells; Transforming growth factor 1

Indexed keywords

ALPHA ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MYOSIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ACETYLATION; ADULT; AGED; ARTICLE; BICUSPID AORTIC VALVE; CELL SPECIFICITY; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; HERITABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MARFAN SYNDROME; METHYLATION; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; THORACIC AORTA ANEURYSM; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE;

ACETYLATION; ADULT; AGED; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; CASE-CONTROL STUDIES; CELLS, CULTURED; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HISTONES; HUMANS; MARFAN SYNDROME; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, MESSENGER; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; YOUNG ADULT;

EID: 78751544035     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq291     Document Type: Article

References (44)

1. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
2. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.
3. Liu C, Gaca MD, Swenson ES, Vellucci VF, Reiss M, Wells RG. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 2003;278:11721-11728.
4. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000;19:1745-1754.
5. Schmierer B, Tournier AL, Bates PA, Hill CS. Mathematical modeling identifies Smad nucleocytoplasmic shuttling as a dynamic signal-interpreting system. Proc Natl Acad Sci USA 2008;105:6608-6613.
6. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-411.
7. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275-281.
8. Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet 2006;38:452-457.
9. Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G et al. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol 2009;218:131-142.
10. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M et al. Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat Genet 1997;15:207-211.
11. Owens GK, Wise G. Regulation of differentiation/maturation in vascular smooth muscle cells by hormones and growth factors. Agents Actions Suppl 1997;48:3-24.
12. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009;120:526-532.
13. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857-869.
14. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-339.
15. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-860.
16. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 2006;38:343-349.
17. Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, Presley C et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet 2007;16:2453-2462.
18. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007;39:1488-1493.
19. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S et al. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet 2008;9:283-302.
20. Roos-Hesselink JW, Scholzel BE, Heijdra RJ, Spitaels SE, Meijboom FJ, Boersma E et al. Aortic valve and aortic arch pathology after coarctation repair. Heart 2003;89: 1074-1077.
21. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005;111: 816-828.
22. Klein DG. Thoracic aortic aneurysms. J Cardiovasc Nurs 2005;20:245-250.
23. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-121.
24. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355: 788-798.
25. Robinson PN, Arteaga-Solis E, Baldock C, Collod-Beroud G, Booms P, De Paepe A et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006;43:769-787.
26. Jones JA, Spinale FG, Ikonomidis JS. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res 2009;46: 119-137.
27. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997;35:2-3.
28. Touat Z, Lepage L, Ollivier V, Nataf P, Hvass U, Labreuche J et al. Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm. Arterioscler Thromb Vasc Biol 2008;28:940-946.
29. Battle T, Arnal JF, Michel JB. Hyperproliferation of aortic smooth muscle cells and fibroblasts from young SHR rats is not shared by endothelial cells. Clin Exp Pharmacol Physiol 1994;21:981-989.
30. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes-but without modulating bone morphogenetic protein 7 signaling. Hepatology 2009;49:2021-2030.
31. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008;105: 9047-9052.
32. Takenoshita S, Mogi A, Nagashima M, Yang K, Yagi K, Hanyu A et al. Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway. Genomics 1998;48:1-11.
33. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005;6:838-849.
34. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H et al. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 2005;24:6765-6772.
35. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002;4:599-604.
36. Mochizuki K, Takabe S, Goda T. Changes on histone H3 modifications on the GLUT5 gene and its expression in Caco-2 cells co-treated with a p44/42 MAPK inhibitor and glucocorticoid hormone. Biochem Biophys Res Commun 2008;371:324-327.
37. Nishida H, Suzuki T, Kondo S, Miura H, Fujimura Y, Hayashizaki Y. Histone H3 acetylated at lysine 9 in promoter is associated with low nucleosome density in the vicinity of transcription start site in human cell. Chromosome Res 2006;14:203-211.
38. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008;99:2107-2112.
39. Izzi L, Attisano L. Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 2004;23:2071-2078.
40. McDonald OG, Owens GK. Programming smooth muscle plasticity with chromatin dynamics. Circ Res 2007;100:1428-1441.
41. Owens GK, Kumar MS,Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
42. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest 2006;116:36-48.
43. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 299:F14-F25.
44. Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 2009;42:711-720.